IASO Biotechnology and Innovent Biologics Inc. have jointly announced a new strategic collaboration. According to the agreement, IASO Bio will purchase Innovent’s relevant rights of FUCASO under the original “BCMA CAR-T Cell Therapy Cooperation Agreement” at the agreed price and Innovent will use the proceeds to acquire an 18% stake in IASO Bio. Under the new strategic cooperation framework, the parties expect to achieve high-level integration in the field of cellular immun...